IMAT-Neuroblastoma

Not Applicable

Active, not recruiting

• Conditions: Specialty: Cancer, Primary sub-specialty: Children's Cancer and Leukaemia; UKCRC code/ Disease: Cancer/ Malignant neoplasms of ill-defined, secondary and unspecified sites; Cancer; Neuroblastoma

• Registration Number: ISRCTN10746820
• Lead Sponsor: niversity of Birmingham

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-13
• Last Update Posted: 2024-07-08
• Study Completion: 2025-02-21

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Any patient with high-risk neuroblastoma of the abdominal or pelvic regions who requires radical radiotherapy
2. Fit to receive radical radiotherapy
3. Aged 18 months or over at diagnosis
4. Informed consent from patient, parent or guardian
5. Documented negative pregnancy test for female patients of child bearing potential
6. Patient agrees to use effective contraception during treatment period (patients of child bearing age)

Exclusion Criteria

Pregnant patient.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The actual dose delivered to patients in Gy, covering total Gy given and in how many fractions is captured by form following end of treatment.